Results 181 to 190 of about 28,857 (204)

Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections

American Journal of Obstetrics and Gynecology, 2022
Stephen Brand, Mahmoud Ghannoum, Stacey Curelop   +2 more
exaly  

Treatment of Vulvovaginal Candidiasis—An Overview of Guidelines and the Latest Treatment Methods

Journal of Clinical Medicine, 2023
Krzysztof Kułak, Bartłomiej Zaremba, Karolina Frankowska   +2 more
exaly  

Oteseconazole: An Advance in Treatment of Recurrent Vulvovaginal Candidiasis

Future Microbiology, 2021
Paul Nyirjesy, Jack Sobel
exaly  

Recurrent Vulvovaginal Candidiasis: An Immunological Perspective

Microorganisms, 2020
Martin Jaeger, Simone Moorlag, Mariolina Bruno   +2 more
exaly  

Vulvovaginal Candidiasis

2022
openaire   +1 more source

Vulvovaginal Candidiasis: A Current Understanding and Burning Questions

Journal of Fungi (Basel, Switzerland), 2020
Junyan Liu, Brian Peters, Zhenbo Xu
exaly  

Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy

Drug Design, Development and Therapy, 2023
exaly  

Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306

Journal of Women's Health, 2023
Mark Spitzer, David Angulo
exaly  

Vulvovaginal candidiasis

2016
openaire   +2 more sources

The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause

Climacteric, 2018
Nick Panay, Rossella Nappi, Santiago Palacios   +2 more
exaly